Genmab CEO hopes for verdict in Johnson & Johnson arbitration soon

Jan van de Winkel, CEO of Genmab, hopes for a fast decision in the arbitration dispute, which concerns Darzalex royalties, with Johnson & Johnson-owned Janssen.
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
by marketwire, trranslated by daniel pedersen

Genmab hopes to soon see a verdict in the large and potentially costly arbitration dispute with partner Johnson & Johnson concerning the rights to the huge revenue inflows from cancer drug Darzalex.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading